Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Leja, Justyna ^a   Nilsson, Berith ^a   Yu, Di ^a   Gustafson, Elisabet ^b   Åkerström, Göran ^b   Öberg, Kjell ^b   Giandomenico, Valeria ^b   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AD[CGA E1A MIR122]; AD[CGA E1A]; CHROMOGRANIN A; E1A PROTEIN; MICRORNA; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ARTICLE; CARCINOID; CELL KILLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REPEATED DRUG DOSE; TANDEM REPEAT; TRANSCRIPTION REGULATION; VIRAL GENE THERAPY; VIRUS INHIBITION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, THEORETICAL; NEOPLASMS; STOCHASTIC PROCESSES;

ADENOVIRIDAE; MUS;

EID: 77749270545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008916     Document Type: Article

References (23)

1. Campos SK, Barry MA (2007) Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204.
2. Waehler R, Russell SJ, Curiel DT (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587.
3. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355.
4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
5. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
6. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591.
7. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, et al. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467.
8. Kelly EJ, Hadac EM, Greiner S, Russell SJ (2008) Engineering micro-RNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283.
9. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, et al. (2009) Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 5: e1000440.
10. Ylosmaki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, et al. (2008) Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 82: 11009-11015.
11. Leja J, Dzojic H, Gustafson E, Oberg K, Giandomenico V, et al. (2007) A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 13: 2455-2462.
12. Feldman SA, Eiden LE (2003) The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 14: 3-23.
13. Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64: 2863-2886.
14. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, et al. (1999) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858-865.
15. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A (2008) miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48: 648-656.
16. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
17. Hitt MM, Graham FL (1990) Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 179: 667-678.
18. Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K, et al. (2008) miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 16: 1719-1726.
19. Danielsson A, Dzojic H, Nilsson B, Essand M (2008) Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther 15: 203-213.
20. Cheng WS, Kraaij R, Nilsson B, van der Weel L, de Ridder CM, et al. (2004) A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther 10: 355-364.
21. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
22. Essand M, Vikman S, Grawe J, Gedda L, Hellberg C, et al. (2005) Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1. J Mol Endocrinol 35: 489-501.
23. Prage L, Pettersson U, Hoglund S, Lonberg-Holm K, Philipson L (1970) Structural proteins of adenoviruses. IV. Sequential degradation of the adenovirus type 2 virion. Virology 42: 341-358.